Cytokinetics_Logo_RGB (1).jpg
Cytokinetics Announces Partnership to Improve Prediction of Risk and Outcomes in Hypertrophic Cardiomyopathy
August 18, 2020 07:30 ET | Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Aug. 18, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced a $1 million grant and four-year partnership with the HCM Registry (HCMR), a...
Cytokinetics_Logo_RGB (1).jpg
Cytokinetics Reports Second Quarter 2020 Financial Results
August 06, 2020 16:00 ET | Cytokinetics, Incorporated
Top-line Results from GALACTIC-HF Expected in Q4 2020 Licensing Collaboration, Royalty Monetizations and Financing Provide Additional Capitalto Support Commercial Development and Pipeline...
Cytokinetics_Logo_RGB (1).jpg
Cytokinetics to Announce Second Quarter Results on August 6, 2020
July 23, 2020 16:00 ET | Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report second quarter results on August 6, 2020 at...
Cytokinetics_Logo_RGB (1).jpg
Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
July 21, 2020 16:00 ET | Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., July 21, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced the closing of its previously announced underwritten public offering of...
Cytokinetics_Logo_RGB (1).jpg
Cytokinetics Announces Pricing of Public Offering of Common Stock
July 16, 2020 23:32 ET | Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., July 16, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced the pricing of an underwritten public offering of 7,291,667 shares of its...
Cytokinetics_Logo_RGB (1).jpg
Cytokinetics Announces Proposed Public Offering of Common Stock
July 15, 2020 16:00 ET | Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., July 15, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced plans to offer, subject to market and other conditions, $150,000,000 of shares...
Cytokinetics_Logo_RGB (1).jpg
Cytokinetics Provides Updates on Its Cardiovascular Pipeline and Strategies to Build a Commercial Franchise at Today’s Virtual Investor & Analyst Day
July 15, 2020 07:30 ET | Cytokinetics, Incorporated
Topline Results from GALACTIC-HF, Phase 3 Clinical Trial of Omecamtiv Mecarbil, Cardiac Myosin Activator, Expected in Q4 Licensing Collaboration and Royalty Monetization Deals with Xi Jing...
Cytokinetics_Logo_RGB (1).jpg
Cytokinetics Announces Licensing Collaboration and Royalty Monetization Deals with RTW Investments Focused to CK-3773274, Next-Generation Cardiac Myosin Inhibitor
July 14, 2020 07:30 ET | Cytokinetics, Incorporated
$250 Million in Committed Capital to Cytokinetics;Additional $200 Million in Development and Commercialization Milestone Payments Ji Xing Pharmaceuticals to Develop & Commercialize in China ...
Cytokinetics_Logo_RGB (1).jpg
Cytokinetics Announces Participation in the Launch of Kainomyx, Inc. Focused to the Treatment of Parasitic Diseases
July 13, 2020 07:30 ET | Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., July 13, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is participating in the launch of Kainomyx, Inc., a new...
Cytokinetics_Logo_RGB (1).jpg
Cytokinetics to Host Virtual Investor & Analyst Day on July 15, 2020
July 01, 2020 16:00 ET | Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., July 01, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK), today announced that it will host a Virtual Investor and Analyst Day on Wednesday, July 15,...